A lethal mice model of recombinant vesicular stomatitis viruses for EBOV-targeting prophylactic vaccines evaluation

Virol Sin. 2024 Jun;39(3):516-519. doi: 10.1016/j.virs.2024.03.008. Epub 2024 Mar 24.

¹ Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
² Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
³ Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China; University of Chinese Academy of Sciences, Beijing, 100049, China; Hubei Jiangxia Laboratory, Wuhan, 430200, China.
⁴ Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China; University of Chinese Academy of Sciences, Beijing, 100049, China; Hubei Jiangxia Laboratory, Wuhan, 430200, China. Electronic address: [email protected].

Abstract

•
The recombinant VSV-EBOV is highly lethal to IFNα/β/γ R^−/− mice.
•
The infected mice exhibit hyperviremia and distinct splenohepatic lesions.
•
Virus replicon particle vaccine can protect all IFNα/β/γ R^−/− mice against VSV-EBOV lethal challenge.
•
This surrogate model can be used for EBOV vaccine evaluation.